Devinder S. Gill
Brisbane, QLD, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
A Heuristic Machine Learning-Based Optimization Technique to Predict Lung Cancer Patient Survival.
Journal: Computational intelligence and neuroscience
Published: July 11, 2022
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
Journal: Acta haematologica
Published: June 24, 2022
SIRPα Suppresses Response to Therapeutic Antibodies by Nurse Like Cells From Chronic Lymphocytic Leukemia Patients.
Journal: Frontiers in immunology
Published: September 26, 2020
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Journal: Annals of hematology
Published: April 15, 2020
Author Correction: Diagnosis of fusion genes using targeted RNA sequencing.
Journal: Nature communications
Published: April 10, 2020
A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Journal: Haematologica
Published: August 16, 2019
High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
Journal: Leukemia & lymphoma
Published: June 26, 2019
PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia.
Journal: Leukemia
Published: January 22, 2019
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: August 25, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Journal: American journal of hematology
Published: August 01, 2018
Last Updated: 09/26/2026